IMpact of PRehabilitation in Oncology Via Exercise - Breast Cancer

Breast Cancer Clinical Trial

— IMPROVE-B  

Official title:

IMpact of PRehabilitation in Oncology Via Exercise - Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03498157
• Other study ID #: PSCI # 17-051
• Status: Completed
• Phase: N/A
• Start date: October 15, 2017
• Est. completion date: July 1, 2019

Study information

• Verified date: January 2020
• Source: Milton S. Hershey Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether patients are able to participate in a so called prehabilitation program (prior to the beginning of cancer treatment) which includes (1) a supervised and home-based exercise program plus one educational session or (2) just home-based exercise plus one educational session or (3) just one educational session.

Breast cancer surgery may have potential for several side effects, including functional (e.g. flexibility in the affected arm, lymphedema [swelling that generally occurs in the arms or legs that occurs as a result of the removal of or damage to lymph nodes as a part of cancer treatment], shoulder pain) and psychosocial (e.g. reduced quality of life, increased fatigue) aspects.

Evidence shows that exercise is considered to be an effective treatment approach in breast cancer patients during and after treatment with regard to the above mentioned side-effects. Also, prehabilitative exercise in colon and lung cancer patients was shown as feasible and effective. However, no experience exits with regard to prehabilitation exercise in breast cancer patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: July 1, 2019
• Est. primary completion date: July 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy

• Not metastatic (stage <4)

• Females and males =18 years of age

• Fluent in written and spoken English

• Must be able to provide and understand informed consent

• Must have an ECOG PS of = 2

• Scheduled for lump- or mastectomy at Penn State Cancer Institute

• = 2 weeks till primary treatment

• Primary attending surgeon approval

Exclusion Criteria:

• Receiving neoadjuvant chemotherapy, radiotherapy or hormone therapy

• Not fluent in written and spoken English

• Evidence in the medical record of an absolute contraindication (e.g. Heart insufficiency > NYHA III or uncertain arrhythmia; uncontrolled hypertension; severe renal dysfunction (GFR < 30%, Creatinine> 3mg/dl; insufficient hematological capacity like either hemoglobin value below 8 g/dl or thrombocytes below 30.000/µL; reduced standing or walking ability) for exercise

• Pregnant women

• Engaging in systematic intense exercise training (at least 1h twice per week)

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Physical Activity
• Prehabilitation
• Surgery

Intervention

Behavioral:
• Exercise
The exercise intervention is an at least 2 weeks lasting (till the day surgery is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
• Prehabilitation Education
Participate will receive a 2 hour group-based prehabilitation class which will be held at the Penn State Cancer Institute, Hershey

Locations

Country	Name	City	State
United States	Penn State Cancer Institute	Hershey	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Milton S. Hershey Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of the exercise intervention (assessed by standardized questionnaire)	Within the questionnaire we will assess whether musculoskeletal occur (yes/no; ongoing; location; severity (mild-life threatening); daily activities affected). The intervention will be considered as safe if less than 25% of included patients report mild musculoskeletal impairments and less than 5% experienced musculoskeletal injuries (defined as symptoms lasting a week or longer and or requiring the attention of a medical professional).	Through study intervention, an average of 3 weeks
Primary	Feasibility of the exercise intervention (assessed via exercise logs)	The exercise intervention will be considered feasible if 50% of included patients actually do at least half of the exercise sessions prescribed for 2 weeks or more.	Through study intervention, an average of 3 weeks
Primary	Acceptability of the exercise intervention (assessed via patient flow diagram)	The intervention will be considered acceptable if more than 50% of the patients randomized to the control group agree to receive at least the first exercise session.	During Recruitment till first intervention is delivered (with one week after enrolment)
Secondary	Health-Related Quality of Life: EORTC QLQ-C30, version 3.0	QoL will be assessed with the validated 30-item self-assessment questionnaire of the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30, version 3.0).	Through study intervention, an average of 3 weeks; 6 weeks after surgery; and after the end of primary treatment, an average of 6 month after surgery
Secondary	Breast cancer-related symptoms and quality of Life	In addition to the EORTC-QLQ-C30 specific breast cancer-related symptoms will be assessed with the validated 23-item breast cancer specific module (EORTC QLQ-BR23). It will assess common problems of breast cancer patients, e.g. with the affected breast or arm	Through study intervention, an average of 3 weeks; 6 weeks after surgery; and after the end of primary treatment, an average of 6 month after surgery
Secondary	Fatigue	Fatigue will be assessed with the Multidimensional Fatigue Inventory (MFI) which is a 20-item, multidimensional self-assessment questionnaire.	Through study intervention, an average of 3 weeks; 6 weeks after surgery; and after the end of primary treatment, an average of 6 month after surgery
Secondary	Sleep	Sleep quality and sleep problems will be assessed with the validated and frequently used Pittsburgh Sleep Quality Index (PSQI)	Through study intervention, an average of 3 weeks; 6 weeks after surgery; and after the end of primary treatment, an average of 6 month after surgery
Secondary	Depression	Depressive symptoms will be assessed with the 20-item Center for Epidemiological Studies Depression Scale (CES-D).	Through study intervention, an average of 3 weeks; 6 weeks after surgery; and after the end of primary treatment, an average of 6 month after surgery
Secondary	Shoulder Problems	The Penn Shoulder Score (PSS) is a 100-point shoulder-specific self-report questionnaire consisting of 3 subscales of pain, satisfaction, and function.	Through study intervention, an average of 3 weeks; 6 weeks after surgery; and after the end of primary treatment, an average of 6 month after surgery
Secondary	Physical activity behavior	Physical activity behavior in the domains of commuting activity, leisure time activities such as cycling, walking, and sports, household and occupational activity will be assessed via a standardized and validated questionnaire, the Short QUestionnaire to ASsess Health-enhancing Physical Activity	Through study intervention, an average of 3 weeks; 6 weeks after surgery; and after the end of primary treatment, an average of 6 month after surgery
Secondary	Symptoms	The revised Edmonton symptom assessment scale is a 10-item patient-rated symptom visual numeric scale developed for use in assessing symptoms of patients receiving palliative care/cancer treatment.	Weekly from baseline to 6 weeks after Surgery